Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial.

Cowling BJ, Perera RAPM, Valkenburg SA, Leung NHL, Iuliano AD, Tam YH, Wong JHF, Fang VJ, Li APY, So HC, Ip DKM, Azziz-Baumgartner E, Fry AM, Levine MZ, Gangappa S, Sambhara S, Barr IG, Skowronski DM, Peiris JSM, Thompson MG.

Clin Infect Dis. 2019 Dec 12. pii: ciz1034. doi: 10.1093/cid/ciz1034. [Epub ahead of print]

PMID:
31828291
2.

Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent.

Gao Z, Robinson K, Skowronski DM, De Serres G, Withers SG.

Vaccine. 2019 Dec 6. pii: S0264-410X(19)31570-1. doi: 10.1016/j.vaccine.2019.11.041. [Epub ahead of print]

PMID:
31818533
3.

Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV).

Skowronski DM, Sabaiduc S, Leir S, Rose C, Zou M, Murti M, Dickinson JA, Olsha R, Gubbay JB, Croxen MA, Charest H, Bastien N, Li Y, Jassem A, Krajden M, De Serres G.

Euro Surveill. 2019 Nov;24(46). doi: 10.2807/1560-7917.ES.2019.24.46.1900585.

4.

Impact of the adolescent pertussis booster dose on the incidence of pertussis in British Columbia and Quebec, Canada.

Brousseau N, Skowronski DM, Bellemare D, Amini R, Joffres Y, Clarke Q, Quach C, Rallu F, Hoang L, De Serres G.

Vaccine. 2019 Nov 1. pii: S0264-410X(19)31443-4. doi: 10.1016/j.vaccine.2019.10.063. [Epub ahead of print]

5.

Nephrotic syndrome following four-component meningococcal B vaccination: Epidemiologic investigation of a surveillance signal.

De Serres G, Billard MN, Gariépy MC, Roy MC, Boucher FD, Gagné H, Belley S, Toth E, Landry M, Skowronski DM.

Vaccine. 2019 Aug 14;37(35):4996-5002. doi: 10.1016/j.vaccine.2019.07.017. Epub 2019 Jul 12.

PMID:
31307873
7.

Evidence in a Cluster Randomized Controlled Trial of Increased 2009 Pandemic Risk Associated With 2008-2009 Seasonal Influenza Vaccine Receipt.

Skowronski DM, De Serres G.

Clin Infect Dis. 2019 Nov 27;69(12):2230-2231. doi: 10.1093/cid/ciz351. No abstract available.

8.

Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: ‎possible cohort effect following the 2009 influenza pandemic.

Skowronski DM, Leir S, De Serres G, Murti M, Dickinson JA, Winter AL, Olsha R, Croxen MA, Drews SJ, Charest H, Martineau C, Sabaiduc S, Bastien N, Li Y, Petric M, Jassem A, Krajden M, Gubbay JB.

Euro Surveill. 2019 Apr;24(15). doi: 10.2807/1560-7917.ES.2019.24.15.1900104.

9.

Caution Required in the Use of Administrative Data and General Laboratory Submissions for Influenza Vaccine Effectiveness Estimation.

Skowronski DM, De Serres G, Orenstein WA.

Clin Infect Dis. 2019 Aug 30;69(6):1084-1085. doi: 10.1093/cid/ciz113. No abstract available.

10.

Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019.

Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, Gubbay JB, Croxen MA, Charest H, Chan T, Bastien N, Li Y, Krajden M, De Serres G.

Euro Surveill. 2019 Jan;24(4). doi: 10.2807/1560-7917.ES.2019.24.4.1900055.

11.

Application of the Test-Negative Design to General Laboratory Submissions.

Skowronski DM, De Serres G.

JAMA Pediatr. 2019 Feb 1;173(2):195-196. doi: 10.1001/jamapediatrics.2018.4370. No abstract available.

PMID:
30535171
12.

Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.

De Serres G, Billard MN, Gariépy MC, Rouleau I, Toth E, Landry M, Boulianne N, Gagné H, Gilca V, Deceuninck G, Ouakki M, Skowronski DM.

Vaccine. 2018 Dec 18;36(52):8039-8046. doi: 10.1016/j.vaccine.2018.10.095. Epub 2018 Nov 19.

PMID:
30467063
13.

Vaccine Effectiveness Against Lineage-matched and -mismatched Influenza B Viruses Across 8 Seasons in Canada, 2010-2011 to 2017-2018.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Fonseca K, Charest H, Martineau C, Hickman R, Chan T, Jassem A, Petric M, Rose C, Bastien N, Li Y, Krajden M.

Clin Infect Dis. 2019 May 2;68(10):1754-1757. doi: 10.1093/cid/ciy876.

14.

Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age.

Kiely M, Billard MN, Toth E, Zafack JG, Landry M, Skowronski DM, De Serres G.

Vaccine. 2018 Oct 29;36(45):6688-6694. doi: 10.1016/j.vaccine.2018.09.049. Epub 2018 Sep 27.

PMID:
30269915
15.

Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?

Chambers C, Skowronski DM, Rose C, Serres G, Winter AL, Dickinson JA, Jassem A, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Petric M, Krajden M.

Open Forum Infect Dis. 2018 Sep 4;5(9):ofy211. doi: 10.1093/ofid/ofy211. eCollection 2018 Sep.

16.

Ecological Fallacy, Nonspecific Outcomes, and the Attribution of Disproportionate Vaccine Benefits.

De Serres G, Skowronski DM.

Clin Infect Dis. 2018 May 17;66(11):1817-1818. doi: 10.1093/cid/ciy014. No abstract available.

17.

Role of Egg-adaptation Mutations in Low Influenza A(H3N2) Vaccine Effectiveness During the 2012-2013 Season.

Skowronski DM, De Serres G.

Clin Infect Dis. 2018 Oct 15;67(9):1474-1476. doi: 10.1093/cid/ciy350. No abstract available.

18.

Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.

Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter AL, Hickman R, Chan T, Jassem AN, Drews SJ, Charest H, Gubbay JB, Bastien N, Li Y, Krajden M.

Euro Surveill. 2018 Feb;23(5). doi: 10.2807/1560-7917.ES.2018.23.5.18-00035. Erratum in: Euro Surveill. 2018 Jul;23(30):.

19.

Selection Bias in the Assessment of Frailty and Its Role in Influenza Vaccine Effectiveness Evaluation Among Elderly Adults.

Skowronski DM, Chambers C, De Serres G.

J Infect Dis. 2017 Dec 27;217(1):168. doi: 10.1093/infdis/jix548. No abstract available.

PMID:
29045721
20.

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Martineau C, Charest H, Krajden M, Bastien N, Li Y.

J Infect Dis. 2017 Dec 19;216(12):1487-1500. doi: 10.1093/infdis/jix526.

21.

Prevalence of risk factors for acquiring measles during the 2011 outbreak in Quebec and impact of the province-wide school-based vaccination campaign on population immunity.

Billard MN, De Serres G, Gariépy MC, Boulianne N, Toth E, Landry M, Skowronski DM.

PLoS One. 2017 Oct 11;12(10):e0186070. doi: 10.1371/journal.pone.0186070. eCollection 2017.

22.

Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010-2011 to 2015-2016, Canada.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y.

J Infect Dis. 2017 Sep 15;216(6):697-702. doi: 10.1093/infdis/jix393.

23.

Reply to Chung et al.

Skowronski DM, Chambers C, De Serres G.

J Infect Dis. 2017 Jul 15;216(2):285-287. doi: 10.1093/infdis/jix287. No abstract available.

PMID:
28633301
24.

Reduced Antibody Response to Infant Measles Vaccination: Effects Based on Type and Timing of the First Vaccine Dose Persist After the Second Dose.

Carazo Perez S, De Serres G, Bureau A, Skowronski DM.

Clin Infect Dis. 2017 Oct 1;65(7):1094-1102. doi: 10.1093/cid/cix510.

PMID:
28595358
25.

Repeated annual influenza vaccination and vaccine effectiveness: review of evidence.

Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G.

Expert Rev Vaccines. 2017 Jul;16(7):1-14. doi: 10.1080/14760584.2017.1334554. Epub 2017 Jun 9. Review. Erratum in: Expert Rev Vaccines. 2017 Aug;16(8):865-866.

PMID:
28562111
26.

Pooling and the Potential Dilution of Repeat Influenza Vaccination Effects.

Skowronski DM, Chambers C.

Clin Infect Dis. 2017 Jul 15;65(2):353-355. doi: 10.1093/cid/cix375. No abstract available.

PMID:
28430894
27.

RE: "DETECTABLE RISKS IN STUDIES OF THE FETAL BENEFITS OF MATERNAL INFLUENZA VACCINATION".

De Serres G, Skowronski DM.

Am J Epidemiol. 2017 May 1;185(9):860-861. doi: 10.1093/aje/kww202. No abstract available.

PMID:
28369245
28.

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.

Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, Drews SJ, Jassem A, Gubbay JB, Charest H, Balshaw R, Bastien N, Li Y, Krajden M.

Euro Surveill. 2017 Feb 9;22(6). pii: 30460. doi: 10.2807/1560-7917.ES.2017.22.6.30460.

29.

Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-2015.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y, Smith DJ.

J Infect Dis. 2017 Apr 1;215(7):1059-1099. doi: 10.1093/infdis/jix074.

30.

Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement.

De Serres G, Skowronski DM, Ward BJ, Gardam M, Lemieux C, Yassi A, Patrick DM, Krajden M, Loeb M, Collignon P, Carrat F.

PLoS One. 2017 Jan 27;12(1):e0163586. doi: 10.1371/journal.pone.0163586. eCollection 2017.

31.

Clinical Approach Used in Medical Consultations for Allergic-Like Events Following Immunization: Case Series Report in Relation to Practice Guidelines.

Zafack JG, De Serres G, Rouleau I, Gariépy MC, Gagnon R, Drolet JP, Skowronski DM.

J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):718-727.e1. doi: 10.1016/j.jaip.2016.09.048. Epub 2016 Nov 30.

PMID:
27914816
32.

Repeat Influenza Vaccination and High-Dose Efficacy.

Skowronski DM, Chambers C, Gilca R, De Serres G.

Clin Infect Dis. 2016 Nov 1;63(9):1265-1266. Epub 2016 Aug 9. No abstract available.

PMID:
27506686
33.

A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Krajden M, Gubbay JB, Drews SJ, Martineau C, Eshaghi A, Kwindt TL, Bastien N, Li Y.

Clin Infect Dis. 2016 Jul 1;63(1):21-32. doi: 10.1093/cid/ciw176. Epub 2016 Mar 29.

34.

Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016.

Chambers C, Skowronski DM, Sabaiduc S, Winter AL, Dickinson JA, De Serres G, Gubbay JB, Drews SJ, Martineau C, Eshaghi A, Krajden M, Bastien N, Li Y.

Euro Surveill. 2016;21(11):30168. doi: 10.2807/1560-7917.ES.2016.21.11.30168.

35.

Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses.

Skowronski DM, Sabaiduc S, Chambers C, Eshaghi A, Gubbay JB, Krajden M, Drews SJ, Martineau C, De Serres G, Dickinson JA, Winter AL, Bastien N, Li Y.

Euro Surveill. 2016;21(3):30112. doi: 10.2807/1560-7917.ES.2016.21.3.30112.

36.

Systematic community- and hospital-based surveillance for enterovirus-D68 in three Canadian provinces, August to December 2014.

Skowronski DM, Chambers C, Sabaiduc S, Murti M, Gustafson R, Pollock S, Hoyano D, Rempel S, Allison S, De Serres G, Dickinson JA, Tellier R, Fonseca K, Drews SJ, Martineau C, Reyes-Domingo F, Wong T, Tang P, Krajden M.

Euro Surveill. 2015;20(43). doi: 10.2807/1560-7917.ES.2015.20.43.30047.

37.

Avian Influenza A(H7N9) Virus Infection in 2 Travelers Returning from China to Canada, January 2015.

Skowronski DM, Chambers C, Gustafson R, Purych DB, Tang P, Bastien N, Krajden M, Li Y.

Emerg Infect Dis. 2016 Jan;22(1):71-4. doi: 10.3201/eid2201.151330.

38.

Detection of influenza A(H3N2) clade 3C.2a viruses in patients with suspected mumps in British Columbia, Canada, during the 2014/15 influenza season.

Chambers C, Skowronski DM, Sabaiduc S, Murti M, Gustafson R, Pollock S, Hoyano D, Allison S, Krajden M.

Euro Surveill. 2015;20(36). doi: 10.2807/1560-7917.ES.2015.20.36.30015. No abstract available.

39.

Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.

De Serres G, Rouleau I, Skowronski DM, Ouakki M, Lacroix K, Bédard F, Toth E, Landry M, Dupré N.

Vaccine. 2015 Aug 26;33(36):4464-71. doi: 10.1016/j.vaccine.2015.07.028. Epub 2015 Jul 22.

40.

Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015.

Gilca R, Skowronski DM, Douville-Fradet M, Amini R, Boulianne N, Rouleau I, Martineau C, Charest H, De Serres G.

PLoS One. 2015 Jul 22;10(7):e0132195. doi: 10.1371/journal.pone.0132195. eCollection 2015.

41.
42.

Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay J, Fonseca K, Charest H, Krajden M, Petric M, Mahmud SM, Van Caeseele P, Bastien N, Eshaghi A, Li Y.

J Infect Dis. 2015 Sep 1;212(5):726-39. doi: 10.1093/infdis/jiv177. Epub 2015 Mar 17.

PMID:
25784728
43.

Other respiratory viruses are important contributors to adult respiratory hospitalizations and mortality even during peak weeks of the influenza season.

Gilca R, Amini R, Douville-Fradet M, Charest H, Dubuque J, Boulianne N, Skowronski DM, De Serres G.

Open Forum Infect Dis. 2014 Sep 22;1(2):ofu086. doi: 10.1093/ofid/ofu086. eCollection 2014 Sep.

44.

Surveillance summary of hospitalized pediatric enterovirus D68 cases in Canada, September 2014.

Edwin JJ, Domingo FR, Booth TF, Mersereau T, Skowronski DM, Chambers C, Simmonds K, Scott AN, Winter AL, Peci A, Gubbay J, Drews SJ, Krajden M, Karnauchow T, Smieja M, Rempel S, Murti M, Pollock S, Gustafson R, Hoyano D, Allison S, Fathima S, Pabbaraju K, Wong S, Tellier R, Tipples G, Gad RR, Mukhi SN, Jafari Y, Grudeski E, McDermid A, Wong T.

Can Commun Dis Rep. 2015 Feb 20;41(Suppl 1):2-8. doi: 10.14745/ccdr.v41is1a01. eCollection 2015 Feb 20.

45.

Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, Drews SJ, Fonseca K, Charest H, Gubbay JB, Petric M, Krajden M, Kwindt TL, Martineau C, Eshaghi A, Bastien N, Li Y.

Euro Surveill. 2015 Jan 29;20(4). pii: 21022. No abstract available.

46.

Case series of rash associated with influenza B in school children.

Skowronski DM, Chambers C, Osei W, Walker J, Petric M, Naus M, Li Y, Krajden M.

Influenza Other Respir Viruses. 2015 Jan;9(1):32-7. doi: 10.1111/irv.12296. Epub 2014 Nov 10.

47.

Pre- and postpandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence, by age, during the 2013-2014 epidemic in Canada.

Skowronski DM, Chambers C, Sabaiduc S, Janjua NZ, Li G, Petric M, Krajden M, Purych D, Li Y, De Serres G.

J Infect Dis. 2015 Jan 1;211(1):109-14. doi: 10.1093/infdis/jiu366. Epub 2014 Jun 27.

PMID:
24973459
48.

Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada.

Rouleau I, De Serres G, Skowronski DM, Drolet JP, Lemire C, Toth E, Landry M.

Vaccine. 2014 Jun 12;32(28):3480-7. doi: 10.1016/j.vaccine.2014.04.059. Epub 2014 Apr 29.

PMID:
24793951
49.

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.

Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, Petric M, Charest H, Bastien N, Kwindt TL, Mahmud SM, Van Caeseele P, Li Y.

PLoS One. 2014 Mar 25;9(3):e92153. doi: 10.1371/journal.pone.0092153. eCollection 2014.

50.

Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014.

Skowronski D, Chambers C, Sabaiduc S, De Serres G, Dickinson J, Winter A, Fonseca K, Gubbay J, Charest H, Petric M, Krajden M, Mahmud S, Van Caeseele P, Kwindt T, Eshaghi A, Bastien N, Li Y.

Euro Surveill. 2014 Feb 6;19(5). pii: 20690. Erratum in: Euro Surveill. 2014;19(6):20698.

Supplemental Content

Loading ...
Support Center